Helene Peyro-Saint-Paul

Blue Bees Therapeutics is a biotechnology company founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay. This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG).

🚨🚑 Société spécialisée dans lanalyse de lactivité aux urgences en temps réel et laffichage des temps dattente 🚑🚨 🚨Focus Santé, avec ses solutions URGENCES CHRONO-Régul ; URGENCES CHRONO-Pro ; URGENCES CHRONO-Bed et URGENCES CHRONO.Com, améliore laccès aux soins non programmés en informant les patients et en développant les outils nécessaires à l’organisation, le pilotage et l’optimisation de services durgences, centres de régulation et établissements de santé sur l’ensemble de votre territoire 🚨 Vous souhaitez une démo ou davantage d’informations ? ~CONTACTEZ-NOUS~ 📌 a.pineau@urgenceschrono.com (Direction commerciale) 📌 contact@urgenceschrono.com ~VISITEZ NOTRE SITE INTERNET~ www.urgenceschrono.net #esanté #transformationdigitale #masante2022 #numerique #segurdelasante #SAS #ARS #Territorialité

In MiMARK, we care for womens health. We are specialized in the discovery, verification and validation of biomarkers to develop new solutions for gynecological patients. Abnormal uterine bleeding affects 14M between women in EU and US yearly (in women between 50 and 75 years old). Diagnosis of endometrial cancer is mandatory for all those women as 10% of those will be diagnosed with the disease. Current diagnosis is based on the pathological examination of an endometrial biopsy (pipelle biopsy), but this fails to diagnose in up to 30% of patients, and provides an inaccurate diagnosis in up to 55% of cases. This failure is associated to the scarce cellularity of the sample. In those cases, invasive diagnosis using histeroscopy needs to be performed. Our solution: WomEC. It is an in vitro diagnostic tool based on the determination of 5 protein biomarkers in uterine fluid samples to provide diagnosis to 100% of patients, rule out endometrial cancer with great specificity, and provide information on histological subtype of the tumor to guide surgical treatment.

Etisense, is a Lyon (FR) based MedTech company specialized in non-invasive physiological monitoring. Etisense develops unique instrumentation solutions for pre-clinical research and development. DECRO, (www.etisense.com),our 1st product is now available to help scientists to perform pre-clinical research differently.

Sensome is an innovative start-up developing a breakthrough sensing technology that can turn invasive medical devices into connected healthcare devices. Sensome is EN ISO 13485:2016 certified.

Nova provides its jinkō clinical trials simulation platform to biotech and pharma companies, academic research centers and not-for-profit organizations. Jinkō® unlocks the potential of modeling & simulation to de-risk and accelerate the R&D of new therapies for the benefit of patients: identify best responders, optimise the drugs regimen, generate synthetic control arms, explore research outcomes that might not be feasible with conventional trials. Predict trial outcomes before advancing to real-world clinical trials and ultimately design studies that are more likely to succeed with Jinkō®.

Blue Bees Therapeutics is a biotechnology company founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay. This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG).

🚨🚑 Société spécialisée dans lanalyse de lactivité aux urgences en temps réel et laffichage des temps dattente 🚑🚨 🚨Focus Santé, avec ses solutions URGENCES CHRONO-Régul ; URGENCES CHRONO-Pro ; URGENCES CHRONO-Bed et URGENCES CHRONO.Com, améliore laccès aux soins non programmés en informant les patients et en développant les outils nécessaires à l’organisation, le pilotage et l’optimisation de services durgences, centres de régulation et établissements de santé sur l’ensemble de votre territoire 🚨 Vous souhaitez une démo ou davantage d’informations ? ~CONTACTEZ-NOUS~ 📌 a.pineau@urgenceschrono.com (Direction commerciale) 📌 contact@urgenceschrono.com ~VISITEZ NOTRE SITE INTERNET~ www.urgenceschrono.net #esanté #transformationdigitale #masante2022 #numerique #segurdelasante #SAS #ARS #Territorialité

In MiMARK, we care for womens health. We are specialized in the discovery, verification and validation of biomarkers to develop new solutions for gynecological patients. Abnormal uterine bleeding affects 14M between women in EU and US yearly (in women between 50 and 75 years old). Diagnosis of endometrial cancer is mandatory for all those women as 10% of those will be diagnosed with the disease. Current diagnosis is based on the pathological examination of an endometrial biopsy (pipelle biopsy), but this fails to diagnose in up to 30% of patients, and provides an inaccurate diagnosis in up to 55% of cases. This failure is associated to the scarce cellularity of the sample. In those cases, invasive diagnosis using histeroscopy needs to be performed. Our solution: WomEC. It is an in vitro diagnostic tool based on the determination of 5 protein biomarkers in uterine fluid samples to provide diagnosis to 100% of patients, rule out endometrial cancer with great specificity, and provide information on histological subtype of the tumor to guide surgical treatment.

DNA Finance is a healthcare financial advisor based in Paris, France. DNA Finance executes strategy consulting, fundraising, and M&A assignments for Life Sciences innovative companies. DNA Finance also provides financial analysis for healthcare listed funds.

Etisense, is a Lyon (FR) based MedTech company specialized in non-invasive physiological monitoring. Etisense develops unique instrumentation solutions for pre-clinical research and development. DECRO, (www.etisense.com),our 1st product is now available to help scientists to perform pre-clinical research differently.